ICI-pneumonitis (n=11) | Control (n=6) | P value | |
Age, years | 68.5 (61.7–72.8) | 65.7 (53.0–75.9) | 0.96 |
Sex | – | – | 0.86 |
Men | 5 (45.5) | 3 (50.0) | |
Women | 6 (54.5) | 3 (50.0) | |
Smoking status | – | – | 0.11 |
Never | 1 (9.1) | 3 (50) | |
Former | 9 (81.8) | 2 (33.3) | |
Active | 1 (9.1) | 1 (16.7) | |
COPD | 3 (27.3) | 2 (33.3) | 0.79 |
Underlying malignancy | |||
NSCLC | 10 (90.9) | 6 (100) | 0.45 |
Melanoma | 1 (9.1) | 0 (0) | |
Immunotherapy regimen | NA | ||
Pembrolizumab | 6 (54.5) | NA | |
Nivolumab | 1 (9.1) | NA | |
Durvalumab | 3 (27.3) | NA | |
Atezolizumab | 1 (9.1) | NA | |
Prior systemic therapy* | 8 (72.7) | NA | NA |
Prior radiotherapy† | 5 (45.5) | NA | NA |
Time from symptom onset to sampling (days) | 17.0 (9.0–19.0) | NA | NA |
Grade‡ | NA | ||
2 | 9 (81.8) | NA | |
3 | 2 (18.2) | NA |
Data are median (IQR) or n (%). The p values are from Mann-Whitney U test for continuous data and Pearson’s χ2 for non-ordered categorical data, all based on a two-sided hypothesis.
*Last administration of chemotherapy at least 4 months prior to sampling.
†Radiotherapy completed at least 3 months prior to sampling.
‡Grading according to Common Terminology Criteria for Adverse Events V.5.0.
COPD, chronic obstructive pulmonary disease; ICI, immune checkpoint inhibitor ; NSCLC, non-small cell lung cancer.